Search
recombinant von Willebrand factor (Vonvendi)
Indications:
- as needed treatment & control of bleeding episodes in adults with von Willebrand disease
Adverse effects:
- generalized pruritus
General
recombinant protein; chimer
von Willebrand factor; vWF; ristocetin cofactor; factor VIII related antigen; contains: von Willebrand antigen 2 (VWF, F8VWF)
hematologic agent
References
- FDA News Release. December 8, 2015
FDA approves first recombinant von Willebrand factor to treat
bleeding episodes.
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm476065.htm